重要性是模型對已發布報導給出的 1–5 分，不是對市場的預測。
已排定事件列上的影響是公司顯著度層級（高/中由圖譜中心度與規模判定；低僅用於人工整理的次要事件），不是對波動幅度的預測。
標記為已確認的財報日期，是 Yahoo Finance 認定由公司確認的；預估表示尚未公布。未加標記的列沒有可查的出處記錄。
經濟數據發布屬於總體經濟、不歸屬任何產業，因此在任何檢視下都會保留。沒有數值的發布表示尚未公布，頁面會直說，而不是顯示為零。
涵蓋被追蹤公司的即將到來的事件；已過去的事件會歸檔，並在可得時補上結果——這些結果都經人工整理並附引用，絕不杜撰。沒有結果的歷史列會顯示「結果待定」。
閉鎖期屆滿或指數調整的列會多出一行算術——將變得可賣出的股數，或指數基金必須買進的股數，以佔流通股的比例表示——依招股說明書或指數編製方法讀出，兩個數字都在該列註明出處。它陳述的是機制，不是價格走勢。由 IPO + 180 天推算出的閉鎖期日期會一直標為預估，直到公司自己說明為止。
10月12日週一 · 今天
10月13日週二
9月29日週二
合作
Kioxia will join Applied Materials’ EPIC Center as an innovation partner. The companies plan joint work on memory structures, multi-chip stacking, advanced packaging and materials engineering for AI memory.
合作
Nurix announced a $7 million research milestone under its existing Pfizer collaboration to develop degrader antibody conjugates. The company said the achievement advances research under the agreement originally signed with Seagen.
Accessibility: Skip TopNav Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer Milestone reflects continued progress in collaboration to develop a novel class of degrader antibody conjugates, or DACs September 29, 2026 07:00 ET | Source: Nurix Therapeutics, Inc. Nurix Therapeutics, Inc. BRISBANE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced t…
產品
Microsoft Research introduced Quine, a research system combining a multimodal world model of biology with scientific tools, literature and laboratory experiments. The team reported early experimental work prioritizing compounds that alter pancreatic cancer cell states.
Skip to main content Research Publications Code, datasets and models Artificial intelligence Audio & acoustics Computer vision Graphics & multimedia Human-computer interaction Human language technologies Search & information retrieval Data platforms and analytics Hardware & devices Programming languages & software engineering Quantum computing Security, privacy & cryptography Systems & networking Algorithms Mathematics Ecology & environment Economics Medical, health & genomics Social sciences Technology for emerging markets Academic programs Events & academic conferences Microsoft Research For…
合作
Tenova was selected to supply an electric arc furnace for Nippon Steel’s Yawata works. GE Vernova’s Direct Feed system will provide power for the furnace as part of the collaboration.
Skip to main content press release Electrification Tenova, in collaboration with GE Vernova, to supply the World’s Largest EAF to Nippon Steel’s Yawata Works 1 min read Tenova , a leading provider of sustainable solutions for the metals and mining industries, has been selected by Nippon Steel Corporation to supply a record-breaking Consteel ® Electric Arc Furnace (EAF) for Nippon Steel’s Yawata Area at Kyushu Works. Tenova has teamed up with GE Vernova , whose Direct Feed system will power the EAF. For more information please visit the Tenova newsroom https://tenova.com/newsroom/press-releases…
監管
GE Vernova Hitachi announced that the NRC issued TVA a construction permit for a BWRX-300 small modular reactor at Clinch River. The company described the decision as the first U.S. construction permit for this reactor design.
Skip to main content press release Nuclear Power NRC issues first U.S. construction permit for a BWRX-300 small modular reactor at Tennessee Valley Authority’s Clinch River site 5 min read Decision advances BWRX-300 deployment in the U.S. and reinforces growing regulatory momentum across North America KNOXVILLE, TN (September 29, 2026) – GE Vernova Hitachi Nuclear Energy (GVH) today welcomed the U.S. Nuclear Regulatory Commission’s (NRC) issuance of a construction permit to the Tennessee Valley Authority (TVA) for a BWRX-300 small modular reactor at its Clinch River site in Oak Ridge, Tennesse…
